Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood
The goal of this study was to explore associations between single-nucleotide polymorphisms (SNPs) and umbilical cord blood concentrations of buprenorphine and its metabolites following maternal administration. This is a sub-study of a prospective observational cohort investigation which included pre...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | Toxicology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214750025002112 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849245800085848064 |
|---|---|
| author | Amelia Monfared Derek E. Murrell Darshan S. Shah Melissa Hoang Stacy D. Brown Sam Harirforoosh |
| author_facet | Amelia Monfared Derek E. Murrell Darshan S. Shah Melissa Hoang Stacy D. Brown Sam Harirforoosh |
| author_sort | Amelia Monfared |
| collection | DOAJ |
| description | The goal of this study was to explore associations between single-nucleotide polymorphisms (SNPs) and umbilical cord blood concentrations of buprenorphine and its metabolites following maternal administration. This is a sub-study of a prospective observational cohort investigation which included pregnant women receiving buprenorphine for opioid use disorder during pregnancy. Following delivery, umbilical cord blood samples were collected and genotyped using a pharmacogenetic panel. The drug and metabolite concentrations were analyzed through liquid chromatography-mass spectrometry, and genetic association analysis was completed using PLINK software. The included neonates (n = 14) had a mean birth weight of 3.00 ± 0.39 kg and were born to mothers receiving a mean buprenorphine dose of 10.29 ± 6.22 mg. Ten concentration groupings (drug, single metabolite, as well as drug/metabolite(s) combinations) produced 18 unique SNP associations. Two significant associations included variations in CYP3A4 and UGT1A1, which play a role in the metabolism of buprenorphine. These preliminary findings suggest potential pharmacogenetic factors influencing fetal drug exposure, warranting larger studies to validate associations and explore clinical implications for neonatal outcomes. |
| format | Article |
| id | doaj-art-6c04aa4633024e3eb364bb5e68ef502e |
| institution | Kabale University |
| issn | 2214-7500 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Toxicology Reports |
| spelling | doaj-art-6c04aa4633024e3eb364bb5e68ef502e2025-08-20T03:58:41ZengElsevierToxicology Reports2214-75002025-12-011510209310.1016/j.toxrep.2025.102093Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord bloodAmelia Monfared0Derek E. Murrell1Darshan S. Shah2Melissa Hoang3Stacy D. Brown4Sam Harirforoosh5School of Pharmacy, Chapman University, Irvine, CA, USAGatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USAQuillen College of Medicine, East Tennessee State University, Johnson City, TN, USASchool of Pharmacy, Chapman University, Irvine, CA, USAGatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USASchool of Pharmacy, Chapman University, Irvine, CA, USA; Correspondence to: Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.The goal of this study was to explore associations between single-nucleotide polymorphisms (SNPs) and umbilical cord blood concentrations of buprenorphine and its metabolites following maternal administration. This is a sub-study of a prospective observational cohort investigation which included pregnant women receiving buprenorphine for opioid use disorder during pregnancy. Following delivery, umbilical cord blood samples were collected and genotyped using a pharmacogenetic panel. The drug and metabolite concentrations were analyzed through liquid chromatography-mass spectrometry, and genetic association analysis was completed using PLINK software. The included neonates (n = 14) had a mean birth weight of 3.00 ± 0.39 kg and were born to mothers receiving a mean buprenorphine dose of 10.29 ± 6.22 mg. Ten concentration groupings (drug, single metabolite, as well as drug/metabolite(s) combinations) produced 18 unique SNP associations. Two significant associations included variations in CYP3A4 and UGT1A1, which play a role in the metabolism of buprenorphine. These preliminary findings suggest potential pharmacogenetic factors influencing fetal drug exposure, warranting larger studies to validate associations and explore clinical implications for neonatal outcomes.http://www.sciencedirect.com/science/article/pii/S2214750025002112PharmacogeneticsPolymorphismBuprenorphineMetabolitesUmbilical cordNeonatal abstinence syndrome |
| spellingShingle | Amelia Monfared Derek E. Murrell Darshan S. Shah Melissa Hoang Stacy D. Brown Sam Harirforoosh Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood Toxicology Reports Pharmacogenetics Polymorphism Buprenorphine Metabolites Umbilical cord Neonatal abstinence syndrome |
| title | Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| title_full | Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| title_fullStr | Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| title_full_unstemmed | Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| title_short | Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| title_sort | pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood |
| topic | Pharmacogenetics Polymorphism Buprenorphine Metabolites Umbilical cord Neonatal abstinence syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2214750025002112 |
| work_keys_str_mv | AT ameliamonfared pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood AT derekemurrell pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood AT darshansshah pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood AT melissahoang pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood AT stacydbrown pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood AT samharirforoosh pharmacogeneticexplorationofbuprenorphineandrelatedmetabolitesinumbilicalcordblood |